查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030044

獸用靜脈輸液市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、適應症、動物類型、最終用途、地區和競爭格局分類，2021-2031年

Veterinary Intravenous Solutions Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Animal type, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸用靜脈輸液市場預計將從 2025 年的 15.1 億美元成長到 2031 年的 22.2 億美元，複合年成長率為 6.63%。

這些靜脈輸液由無菌溶液組成，透過腸外途徑輸注給動物，以確保充足的水分、維持電解質平衡、提供必需營養素並促進藥物給藥。該領域的成長主要受全球伴侶動物數量增加以及將寵物視為家庭成員的趨勢日益成長的推動，這顯著提高了對先進獸醫護理的需求。此外，需要重症監護和支持療法的動物疾病盛行率不斷上升，也對市場擴張起到了重要作用。作為衡量該行業規模的指標，HealthforAnimals 的報告顯示，2024 年全球 20 家領先的動物用藥品公司的總銷售額將達到 386 億美元。

市場概覽
預測期 2027-2031
市場規模：2025年 15.1億美元
市場規模：2031年 22.2億美元
複合年成長率：2026-2031年 6.63%
成長最快的細分市場 伴侶動物
最大的市場 北美洲

儘管取得了這些積極進展，但諸如影響醫藥級原料和成品靜脈注射製劑的全球供應鏈中斷等複雜挑戰，可能會阻礙市場成長。這些物流瓶頸經常導致嚴重的庫存短缺，從而推高全球獸醫醫院和診所的營運成本。

市場促進因素

動物疾病的日益增多是全球獸用靜脈輸液市場的主要驅動力，顯著提升了對依賴輸液療法的診斷、治療和支持性護理的需求。隨著獸醫專業人員治療複雜和慢性疾病的機會越來越多，用於維持水合作用、營養、電解質平衡和藥物輸送的靜脈輸液需求也隨之激增。許多常見健康問題需要長期或反覆的靜脈輸液治療，以穩定急性症狀、促進術後恢復或控制慢性疾病。 Nationwide Pet Insurance 2024 年的數據顯示，犬類十大健康問題中有六項、貓類十大健康問題中有七項是由慢性疾病引起的，這凸顯了伴侶動物持續且日益成長的醫療需求。

同時，全球寵物飼養量的激增以及人們日益成長的將寵物視作家人的文化觀念，顯著提升了對高品質獸醫服務（包括靜脈輸液治療）的需求。隨著人們越來越將寵物視為珍貴的家庭成員，他們也更願意為先進的治療、緊急救生手術和複雜的外科手術付費。這種日益加深的情感紐帶直接轉化為獸醫支出的增加，並促進了全面護理的普及。美國寵物用品協會 (APPA) 的報告也印證了這一趨勢：到 2025 年，美國與寵物相關的支出將達到 1,580 億美元，比上一年成長 3.7%。強勁的財政支持使獸醫能夠實施更廣泛的臨床治療，包括根據個體需求量身定做的靜脈輸液治療。產業領導者，例如碩騰 (Zoetis)，也進一步印證了這一趨勢，該公司 2024 年的總銷售額達到 93 億美元。

市場挑戰

全球供應鏈中斷是獸用靜脈輸液治療產業發展的主要障礙。這些物流挑戰源自於難以採購必要的藥用級原料以及難以保證成品靜脈輸液產品的及時交付。因此，這些供應瓶頸導致全球動物醫院和獸醫診所普遍出現庫存短缺，迫使醫療專業人員應對取得必要治療方法的難題。此外，通路的這種不確定性也推高了動物醫療機構的日常營運成本。

這些物流障礙的嚴重性體現在主要專業組織正在採取的策略性措施。歐洲獸醫協會（FVE）在2025年度報告中指出，該協會全年開展了60項正式磋商，將基本藥物的穩定供應列為首要政策目標。這些專項努力表明，供應鏈不穩定對基本動物用藥品藥物的成本和可及性造成了多麼嚴重的衝擊，最終阻礙了醫療保健服務的可靠提供，並抑制了靜脈注射藥物市場的進一步商業性擴張。

市場趨勢

靜脈輸液和病患監測設備的科技進步是一大趨勢，顯著提高了獸醫輸液治療的安全性和準確性。這些進步包括智慧輸液泵，它能確保精準的輸液速度，並與監護設備無縫整合，提供即時生理指標，使獸醫能夠快速調整治療方案。此類技術改進帶來了更佳的臨床療效，尤其是在重症患者中，即使是輸液量的輕微誤差也可能導致嚴重的併發症。例如，IDEXX Laboratories 在 2026 年 2 月 2 日發布的 2025 年第四季及全年財報中指出，其 CAG Diagnostics醫療設備部門的銷售額年增 69%，顯示獸醫在先進診斷和重症監護監測工具方面的投資強勁成長。

另一個值得關注的趨勢是平衡等滲透壓晶體液的廣泛應用，這源於人們對動物生理學的更深入了解以及臨床上預防因體液類型失衡而引起的併發症需求。這些液體旨在忠實地模擬血漿的天然電解質組成，對於維持適當的酸鹼平衡和降低高氯性酸中毒等風險至關重要。其使用量的增加凸顯了從常規獸醫診療到重症監護等各個環節，體液管理策略正朝著高度客製化和精細化的方向發展。臨床管理的挑戰進一步強調了改善基礎治療的迫切性。例如，2025年4月14日發表在《今日獸醫實踐》（Today's Veterinary Practice）上的報導指出，一項針對276只住院犬的研究發現，僅有27%的治療日實現了正能源平衡，這強調了全面且符合生理措施符合最佳狀態的患者干涉措施的綜合措施。

目錄

第1章 產品概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球獸用靜脈輸液市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（等滲晶體溶液、合成膠體溶液、血液製品、葡萄糖溶液、腸外營養）
    • 適應症（糖尿病酮酸症、胰臟炎、炭疽、慢性腎臟病等）
    • 動物類型（伴侶動物、生產動物）
    • 依最終用途（獸醫院、研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美獸用靜脈輸液市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲獸用靜脈輸液市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區獸用靜脈輸液市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲獸用靜脈輸液市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美獸用靜脈輸液市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球獸用靜脈輸液市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Baxter International Inc.
  • B. Braun SE
  • ICU Medical, Inc.
  • Fresenius Kabi AG
  • Dechra Pharmaceuticals PLC
  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Virbac SA
  • Vetoquinol SA
  • Merck & Co., Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16229

The Global Veterinary Intravenous (IV) Solutions Market is anticipated to expand from USD 1.51 billion in 2025 to USD 2.22 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.63%. These solutions consist of sterile fluids delivered parenterally to animals to ensure proper hydration, maintain electrolyte balance, provide vital nutrients, and facilitate medication delivery. Growth in this sector is primarily driven by the worldwide increase in companion animal ownership and the growing trend of treating pets as family members, which significantly elevates the demand for sophisticated veterinary care. Additionally, the increasing prevalence of animal diseases that require intensive and supportive therapies plays a crucial role in propelling market advancement. Highlighting the scale of this industry, HealthforAnimals reported that the 20 leading animal health companies worldwide achieved a collective revenue of $38.6 billion in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.51 Billion
Market Size 2031USD 2.22 Billion
CAGR 2026-20316.63%
Fastest Growing SegmentCompanion Animal
Largest MarketNorth America

Despite this positive trajectory, market growth faces potential setbacks due to the intricate challenges of global supply chain interruptions affecting pharmaceutical-grade raw materials and completed IV products. These logistical bottlenecks frequently lead to critical inventory shortages and drive up operational expenses for veterinary practices and animal hospitals around the world.

Market Driver

The escalating prevalence of diverse animal illnesses is a major catalyst for the Global Veterinary Intravenous (IV) Solutions Market, significantly boosting the requirement for diagnostic, therapeutic, and supportive interventions that rely on fluid therapy. With veterinary professionals increasingly treating intricate and chronic ailments, there is a surging need for IV fluids to manage rehydration, nutrient infusion, electrolyte stabilization, and drug delivery. Numerous common health issues require prolonged or recurring IV treatments for stabilizing acute episodes, aiding post-operative healing, or managing persistent diseases. Illustrating this point, 2024 data from Nationwide Pet Insurance revealed that chronic illnesses accounted for six of the top ten health concerns in dogs and seven of the top ten in cats, emphasizing the ongoing and rigorous medical needs of companion animals.

Concurrently, surging global pet ownership and the widespread cultural shift toward pet humanization heavily fuel the need for premium veterinary services, including intravenous therapies. As people increasingly regard their pets as cherished family members, they are much more inclined to fund advanced medical procedures, critical emergency care, and intricate surgeries. This deepened emotional connection directly results in heightened veterinary spending, which fosters the widespread use of thorough medical treatments. Underscoring this development, the American Pet Products Association noted that pet expenditures in the United States hit $158 billion in 2025, marking a 3.7% rise from the prior year. Such robust financial backing empowers veterinarians to implement a wider array of clinical therapies, including tailored IV solutions, a trend further validated by major industry entities like Zoetis, which recorded a total 2024 revenue of $9.3 billion.

Market Challenge

Interruptions within global supply networks pose a formidable barrier to the growth of the veterinary intravenous (IV) solutions sector. These logistical hurdles stem from difficulties in sourcing essential pharmaceutical-grade ingredients and maintaining the punctual distribution of completed IV products. Consequently, these supply bottlenecks lead to widespread inventory deficits in animal hospitals and veterinary clinics globally, forcing medical professionals to navigate the scarce availability of indispensable therapies. Additionally, the unpredictable nature of these distribution channels drives up the daily operational expenses for veterinary healthcare facilities.

The severity of these logistical obstacles is highlighted by the strategic initiatives implemented by leading professional organizations. In its 2025 Annual Report, the Federation of Veterinarians of Europe (FVE) noted that it addressed 60 formal consultations over the year, designating the secure supply of crucial medications as a primary policy objective. This dedicated involvement demonstrates how deeply supply chain inconsistencies affect the cost and availability of critical veterinary drugs, which ultimately disrupts the reliable delivery of animal healthcare and impedes the broader commercial expansion of the IV solutions market.

Market Trends

Technological progress in intravenous fluid administration and patient monitoring devices constitutes a major market trend, vastly improving the safety and accuracy of fluid therapy in veterinary medicine. These developments feature intelligent infusion pumps that guarantee precise delivery rates while seamlessly syncing with monitoring equipment to supply real-time physiological metrics, allowing practitioners to swiftly modify treatment plans. Such enhanced technological functionalities lead to superior clinical outcomes, particularly for critical patients where minor miscalculations in fluid dosage can result in severe complications. Demonstrating this shift, IDEXX Laboratories reported a 69% organic revenue surge for its CAG Diagnostics capital instruments in its Fourth Quarter and Full Year 2025 Results published on February 2, 2026, signaling a robust increase in veterinary investments for sophisticated diagnostic and critical care monitoring tools.

Another prominent trend is the widespread integration of balanced isotonic crystalloids, motivated by an advanced comprehension of animal physiology and the clinical need to prevent complications linked to unbalanced fluid types. Formulated to closely replicate the natural electrolyte makeup of blood plasma, these solutions are vital for sustaining proper acid-base equilibrium and mitigating risks like hyperchloremic acidosis. Their escalating use highlights a broader transition toward highly customized and sophisticated fluid administration strategies across routine and intensive veterinary environments. The critical need to refine baseline treatments is further evidenced by clinical management difficulties; for example, an April 14, 2025, article in Today's Veterinary Practice titled "Preventing Malnutrition in Critical Care Patients" noted that a study of 276 hospitalized dogs achieved a positive energy balance on merely 27% of treatment days, emphasizing the essential necessity for holistic and physiologically optimal patient interventions, including advanced fluid therapies.

Key Market Players

  • Baxter International Inc.
  • B. Braun SE
  • ICU Medical, Inc.
  • Fresenius Kabi AG
  • Dechra Pharmaceuticals PLC
  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Virbac S.A.
  • Vetoquinol S.A.
  • Merck & Co., Inc.

Report Scope

In this report, the Global Veterinary Intravenous (IV) Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Intravenous (IV) Solutions Market, By Product

  • Isotonic crystalloids
  • Synthetic colloids
  • Blood products
  • Dextrose solutions
  • Parenteral nutrition

Veterinary Intravenous (IV) Solutions Market, By Indication

  • Diabetic Ketoacidosis
  • Pancreatitis
  • Anthrax
  • Chronic Kidney Disease
  • Others

Veterinary Intravenous (IV) Solutions Market, By Animal type

  • Companion Animals
  • Production Animals

Veterinary Intravenous (IV) Solutions Market, By End Use

  • Veterinary Hospitals
  • Research Institutes
  • Others

Veterinary Intravenous (IV) Solutions Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Intravenous (IV) Solutions Market.

Available Customizations:

Global Veterinary Intravenous (IV) Solutions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Intravenous (IV) Solutions Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Isotonic crystalloids, Synthetic colloids, Blood products, Dextrose solutions, Parenteral nutrition)
    • 5.2.2. By Indication (Diabetic Ketoacidosis, Pancreatitis, Anthrax, Chronic Kidney Disease, Others)
    • 5.2.3. By Animal type (Companion Animals, Production Animals)
    • 5.2.4. By End Use (Veterinary Hospitals, Research Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Veterinary Intravenous (IV) Solutions Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Animal type
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Intravenous (IV) Solutions Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Animal type
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Veterinary Intravenous (IV) Solutions Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Animal type
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Veterinary Intravenous (IV) Solutions Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Animal type
        • 6.3.3.2.4. By End Use

7. Europe Veterinary Intravenous (IV) Solutions Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By Animal type
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Intravenous (IV) Solutions Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Animal type
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Veterinary Intravenous (IV) Solutions Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Animal type
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Veterinary Intravenous (IV) Solutions Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Animal type
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Veterinary Intravenous (IV) Solutions Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Animal type
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Veterinary Intravenous (IV) Solutions Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Animal type
        • 7.3.5.2.4. By End Use

8. Asia Pacific Veterinary Intravenous (IV) Solutions Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By Animal type
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Veterinary Intravenous (IV) Solutions Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Animal type
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Veterinary Intravenous (IV) Solutions Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Animal type
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Veterinary Intravenous (IV) Solutions Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Animal type
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Veterinary Intravenous (IV) Solutions Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Animal type
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Veterinary Intravenous (IV) Solutions Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Animal type
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Veterinary Intravenous (IV) Solutions Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By Animal type
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Veterinary Intravenous (IV) Solutions Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Animal type
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Veterinary Intravenous (IV) Solutions Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Animal type
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Veterinary Intravenous (IV) Solutions Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Animal type
        • 9.3.3.2.4. By End Use

10. South America Veterinary Intravenous (IV) Solutions Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By Animal type
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Veterinary Intravenous (IV) Solutions Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Animal type
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Veterinary Intravenous (IV) Solutions Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Animal type
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Veterinary Intravenous (IV) Solutions Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Animal type
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Veterinary Intravenous (IV) Solutions Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Baxter International Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. B. Braun SE
  • 15.3. ICU Medical, Inc.
  • 15.4. Fresenius Kabi AG
  • 15.5. Dechra Pharmaceuticals PLC
  • 15.6. Zoetis Inc.
  • 15.7. Elanco Animal Health Incorporated
  • 15.8. Virbac S.A.
  • 15.9. Vetoquinol S.A.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer